
Biotech Showcase™ 2023
January 09, 2023
San Francisco, USA
Join Bioxodes at the Biotech Showcase™ 2023. Marc Dechamps, our CEO, will present a corporate overview on Tuesday, January 10, 2023, at 11:30 am PST.
We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice
Cookies settings I agree I refuseCookies information
Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:
These settings will be kept for 24h
Bioxodes’ innovative pipeline includes a clinical-stage program for the prevention of thrombosis and neuroinflammation in patients with an intracerebral hemorrhage (ICH).
Neuroinflammation plays a critical role in the neurologic decline of ICH patients. Ir-CPI, the lead drug candidate of this program, exhibits a unique mechanism of action by targeting coagulation factors (FXIIa & FXIa) and neutrophils, key driver components of the neuroinflammatory process. Ir-CPI prevents blood clot formation without increasing the bleeding risk — a major asset in ICH patients — due to the specific coagulation factors targeted by this compound.
In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of Ir-CPI against neutrophil activation and neutrophil extracellular trap (NET) formation.
Our innovative pipeline includes a clinical-stage program with Ir-CPI for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients. The initiation of the Phase IIa program to collect safety data and first evidence of efficacy in patients is expected early 2023.
Our first-in-class drug candidate with a unique mechanism of action on neutrophils and coagulation factors (FXIa and FXIIa).
Bioxodes is building an innovative pipeline with drug candidates for the prevention of thrombo-inflammatory and inflammatory diseases.
Clinical trials are being conducted to assess the safety and efficacy of Ir-CPI with a primary focus on hemorrhagic stroke.
Biotech Showcase™ 2023
January 09, 2023
San Francisco, USA
Join Bioxodes at the Biotech Showcase™ 2023. Marc Dechamps, our CEO, will present a corporate overview on Tuesday, January 10, 2023, at 11:30 am PST.
Bioxodes to present at Biotech Showcase™ 2023
December 15, 2022
Gosselies, Belgium
Bioxodes to present at Biotech Showcase™ 2023 about its breakthrough drug candidate Ir-CPI for the prevention of thrombosis and neuroinflammation in hemorrhagic stroke patients.
Bioxodes appoints Marc Dechamps as new CEO
October 18, 2022
Marche-en-Famenne, Belgium
HealthTech Innovation Days #4
October 13, 2022
Paris, France
Join Bioxodes at the HTID#4. We'll be happy to discuss about our lead product Ir-CPI and the new developments in intracerebral haemorrhage.
Bioxodes is a Belgian private company, founded in 2013. The Company has received fundings from both the public and private investors.
All investors